{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:38:40Z","timestamp":1784547520848,"version":"3.55.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"Background<\/jats:title>Cancer chemotherapy is a treatment that systematically kills cancer cells but causes expected side effects, known as chemotherapy-induced toxicities. These toxicities are managed with supportive care medications. This study aimed to determine the prescription patterns of supportive care medications in children receiving chemotherapy at a major referral hospital in Tanzania.<\/jats:p><\/jats:sec>Methodology<\/jats:title>A hospital-based descriptive cross-sectional study was conducted at Bugando Medical Centre (BMC). The study analyzed 104 prescription slips of pediatric cancer patients receiving chemotherapy and qualitatively assessed national guidelines and disease-specific protocols used in guiding treatment. Data were cleaned in Microsoft Excel, analyzed using STATA version 15, and presented as frequencies, percentages, and narrative summaries.<\/jats:p><\/jats:sec>Results<\/jats:title>Ondansetron (84.6%) and pre-hydration normal saline (20.2%) were the most prescribed pre-chemotherapy supportive care medications. Similarly, oral ondansetron (80.8%) and post-hydration normal saline (22.1%) were the most prescribed post-chemotherapy medications. Few prescriptions included a combination of antiemetics, fluids, and proton pump inhibitors for regimens with multiple chemotherapeutic agents. National cancer treatment guidelines lacked detailed sections on supportive care medications, leaving prescribing decisions to clinicians, while Burkitt\u2019s lymphoma and nephroblastoma protocols offered more detailed guidance.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Antiemetics and hydration fluids dominated supportive care prescriptions. Significant gaps were identified in the inclusion of supportive care in national guidelines, with reliance on disease-specific protocols. These findings highlight the need for standardized, evidence-based supportive care guidelines tailored to resource-limited settings.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1444565","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:11:09Z","timestamp":1740460269000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Prescription patterns of supportive care medications among children receiving chemotherapy treatments at a major referral hospital in Tanzania: where are we in managing chemotherapy-induced toxicities?"],"prefix":"10.3389","volume":"15","author":[{"given":"Deogratias M.","family":"Katabalo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benson R.","family":"Kidenya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Liwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"B1","volume-title":"Cancer chemotherapy","author":"Amjad","year":"2020"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.3390\/s23031482","article-title":"Biomarkers and corresponding biosensors for childhood cancer diagnostics","volume":"23","author":"Gharehzadehshirazi","year":"2023","journal-title":"Sensors"},{"key":"B3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2352-4642(22)00161-4","article-title":"Tackling childhood cancer in sub-Saharan Africa","volume":"6","author":"Health","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.2016.009027","article-title":"Pediatric cancer in Northern Tanzania: evaluation of diagnosis, treatment, and outcomes","volume":"4","author":"Schroeder","year":"2017","journal-title":"J Glob Oncol"},{"key":"B5","volume-title":"Childhood cancer and functional impacts across the care continuum","year":"2020"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2022","journal-title":"Genes Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3390\/children10010149","article-title":"Diagnosis and management of cancer treatment-related cardiac dysfunction and heart failure in children","volume":"10","author":"Hegazy","year":"2023","journal-title":"Children"},{"key":"B8","first-page":"228","article-title":"Management and preventive measures for febrile neutropenia","volume":"43","author":"Lucas","year":"2018","journal-title":"Pharm Ther"},{"key":"B9","first-page":"232","article-title":"Chemotherapy-induced nausea and vomiting: optimizing prevention and management","volume":"5","author":"Rao","year":"2012","journal-title":"Am Health Drug Benefits"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.776541","article-title":"Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients","volume":"14","author":"Janelsins","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"B11","unstructured":"What is supportive care"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1596\/978-1-4648-0349-9_ch7","article-title":"Treating childhood cancer in low-and middle-income countries","volume":"3","author":"Gupta","year":"2015","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3889\/oamjms.2019.249","article-title":"The assessment of drug utilization study of anticancer drugs using who prescribing indicators in a government tertiary care hospital of the Hyderabad-Karnataka Region of India","volume":"7","author":"Bepari","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.12688\/f1000research","article-title":"Drug utilization pattern and adverse drug reactions of chemotherapy in pediatric patients at Muhimbili National Hospital, Tanzania","volume":"11","author":"Efraim","year":"2022","journal-title":"F1000Research"},{"key":"B15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1158\/1538-7755.ASGCR21-101","article-title":"The Tanzanian Pediatric Cancer Network: A comprehensive evaluation of the incidence of presenting patients and access to pediatric cancer care in Tanzania","volume":"30","author":"Maillie","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/GO.22.00263","article-title":"Childhood and adolescent cancer care at a tertiary hospital in northern Tanzania: A retrospective study","volume":"9","author":"Majaliwa","year":"2023","journal-title":"JCO Glob Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4103\/ijmpo.ijmpo_156_18","article-title":"Drug utilization evaluation of anticancer drugs in a charitable hospital","volume":"40","author":"Mathew","year":"2019","journal-title":"Indian J Med Paediatr Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3390\/ph17050616","article-title":"Anti-emetics in children receiving chemotherapy for solid tumors and leukemia: pharmacology and optimization of therapy for nausea and vomiting","volume":"17","author":"Ganguly","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25915","article-title":"Chemotherapy-induced nausea and vomiting prophylaxis: practice within the Children\u2019s Oncology Group","volume":"63","author":"Patel","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"B20","article-title":"A study on prescribing trends of supportive care drugs used in cancer chemotherapy in a tertiary care teaching hospital","volume":"6","author":"Ramalakshmi","year":"2013","journal-title":"Indian J Pharm Pract"},{"key":"B21","article-title":"The most common side effects experienced by patients were receiving first cycle of chemotherapy","volume":"47","author":"Altun","year":"2018","journal-title":"Iran J Public Health"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/1043454214532024","article-title":"Evidence-based practice recommendations for hydration in children and adolescents with cancer receiving intravenous cyclophosphamide","volume":"31","author":"Robinson","year":"2014","journal-title":"J Pediatr Oncol Nurs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1749604","article-title":"Supportive care medications coinciding with chemotherapy among children with hematologic Malignancy","volume":"61","author":"Biltaji","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B24","article-title":"Prescribing pattern of antiemetics in the treatment of chemotherapy induced nausea and vomiting","volume":"3","author":"Sahib","year":"2014","journal-title":"World J Pharm Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1482","article-title":"Real-world emetic risk of chemotherapy and the corresponding antiemetic therapy in Japan: a study based on a nationwide database","volume":"5","author":"Okuyama","year":"2022","journal-title":"Cancer Rep"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1444565\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:11:13Z","timestamp":1740460273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1444565\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":25,"alternative-id":["10.3389\/fonc.2025.1444565"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1444565","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"article-number":"1444565"}}